Springhill Fund Asset Management HK Co Ltd Makes New Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Springhill Fund Asset Management HK Co Ltd bought a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 131,200 shares of the company's stock, valued at approximately $3,091,000. Dyne Therapeutics comprises about 5.0% of Springhill Fund Asset Management HK Co Ltd's holdings, making the stock its 11th largest position. Springhill Fund Asset Management HK Co Ltd owned 0.13% of Dyne Therapeutics at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Wells Fargo & Company MN increased its stake in shares of Dyne Therapeutics by 54.5% in the 4th quarter. Wells Fargo & Company MN now owns 38,754 shares of the company's stock valued at $913,000 after acquiring an additional 13,677 shares in the last quarter. Trexquant Investment LP increased its stake in Dyne Therapeutics by 95.6% in the fourth quarter. Trexquant Investment LP now owns 125,378 shares of the company's stock valued at $2,954,000 after purchasing an additional 61,288 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Dyne Therapeutics by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 1,887,329 shares of the company's stock valued at $44,476,000 after purchasing an additional 27,916 shares during the period. Schroder Investment Management Group boosted its position in shares of Dyne Therapeutics by 63.3% during the 4th quarter. Schroder Investment Management Group now owns 147,002 shares of the company's stock worth $3,477,000 after purchasing an additional 56,961 shares in the last quarter. Finally, Pictet Asset Management Holding SA grew its stake in shares of Dyne Therapeutics by 6.2% in the 4th quarter. Pictet Asset Management Holding SA now owns 323,552 shares of the company's stock valued at $7,623,000 after buying an additional 18,847 shares during the period. Institutional investors own 96.68% of the company's stock.

Insiders Place Their Bets

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now directly owns 199,087 shares of the company's stock, valued at approximately $2,777,263.65. The trade was a 1.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 6,237 shares of company stock valued at $77,760 in the last quarter. Insiders own 20.77% of the company's stock.

Analyst Upgrades and Downgrades

DYN has been the topic of several recent research reports. Baird R W upgraded Dyne Therapeutics to a "strong-buy" rating in a report on Thursday, December 12th. HC Wainwright reissued a "buy" rating and set a $46.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 17th. BMO Capital Markets began coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They set an "outperform" rating and a $50.00 price target for the company. JPMorgan Chase & Co. lowered their price objective on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a research note on Friday, March 21st. Finally, Chardan Capital reaffirmed a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Dyne Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $47.46.

Dyne Therapeutics Stock Down 0.6 %

Shares of Dyne Therapeutics stock traded down $0.04 during trading on Friday, hitting $6.94. 355,427 shares of the stock traded hands, compared to its average volume of 2,288,924. The stock has a market cap of $784.72 million, a price-to-earnings ratio of -1.95 and a beta of 1.21. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $47.45. The firm's fifty day moving average is $12.02 and its 200-day moving average is $21.53.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.04. On average, analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.